BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/4/2014 2:22:00 PM | Browse: 1365 | Download: 1282
 |
Received |
|
2012-12-03 21:53 |
|
Peer-Review Started |
|
2012-12-04 17:04 |
 |
First Decision by Editorial Office Director |
|
|
|
Return for Revision |
|
2012-12-19 16:08 |
|
Revised |
|
2012-12-26 14:01 |
|
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2013-01-18 19:08 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2013-01-19 02:31 |
|
Articles in Press |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2013-03-04 15:30 |
|
Publish the Manuscript Online |
|
2013-03-29 14:58 |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Case Report |
| Article Title |
Complete remission of advanced hepatocellular carcinoma by sorafenib: A case report
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Min Su Kim, Young-Joo Jin, Jin-Woo Lee, Jung-il Lee, Young Soo Kim, Sun Young Lee and Myoung Hun Chae |
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Inha University Research Grant |
|
|
| Corresponding Author |
Jin-Woo Lee, MD, PhD, Department of Internal Medicine, Inha University Hospital, Inha University School of Medicine, 7-206, 3-Ga, Shinheung-Dong, Jung-Gu, Incheon 400-711, South Korea. jin@inha.ac.kr |
| Key Words |
Hepatocellular carcinoma; Sorafenib; Portal vein thrombosis; Complete remission |
| Core Tip |
|
| Publish Date |
2013-03-29 14:58 |
| Citation |
Kim MS, Jin YJ, Lee JW, Lee JI, Kim YS, Lee SY, Chae MH. Complete remission of advanced hepatocellular carcinoma by sorafenib: A case report. World J Gastrointest Oncol 2013; 5(2): 38-42 |
| URL |
http://www.wjgnet.com/1948-5204/full/v5/i2/38.htm |
| DOI |
http://dx.doi.org/10.4251/wjgo.v5.i2.38 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
